http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100560102-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-775 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-775 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate | 2004-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100560102-B1 |
| titleOfInvention | Proapolipoprotein A-I variants and antilipidemia or arteriosclerosis comprising the same |
| abstract | The present invention relates to a proapolipoprotein A-1 variant and an agent for preventing and treating hyperlipidemia or atherosclerosis comprising the same, and more specifically, Arg-His-Phe-Trp at the amino acid terminal of apolipoprotein (apoA-I). Variant of proapo AI containing a mutation at position 154, 155, 156, 157 or 158 of apo AI in a proapoprotein comprising -Gln-Gln, a nucleic acid encoding said variant The present invention relates to a recombinant vector comprising the nucleic acid, a transformant transfected with the vector, and a hyperlipidemia or arteriosclerosis prevention and treatment agent containing the variant as an active ingredient.n n n n Proapolipoprotein A-I Variants, Hyperlipidemia, Atherosclerosis |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100863068-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013100292-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101304017-B1 |
| priorityDate | 2004-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 149.